Cantel Medical Corp. (CMN) : Arbor Capital Management reduced its stake in Cantel Medical Corp. by 28.83% during the most recent quarter end. The investment management company now holds a total of 55,834 shares of Cantel Medical Corp. which is valued at $4,006,648 after selling 22,619 shares in Cantel Medical Corp. , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.Cantel Medical Corp. makes up approximately 2.01% of Arbor Capital Management’s portfolio.
Other Hedge Funds, Including , Schwab Charles Investment Management Inc boosted its stake in CMN in the latest quarter, The investment management firm added 6,608 additional shares and now holds a total of 126,662 shares of Cantel Medical Corp. which is valued at $9,089,265. Cantel Medical Corp. makes up approx 0.01% of Schwab Charles Investment Management Inc’s portfolio.Zebra Capital Management reduced its stake in CMN by selling 10,265 shares or 76.43% in the most recent quarter. The Hedge Fund company now holds 3,166 shares of CMN which is valued at $227,192. Cantel Medical Corp. makes up approx 0.08% of Zebra Capital Management’s portfolio.Champlain Investment Partners reduced its stake in CMN by selling 5,920 shares or 0.88% in the most recent quarter. The Hedge Fund company now holds 670,635 shares of CMN which is valued at $48,124,768. Cantel Medical Corp. makes up approx 0.79% of Champlain Investment Partners’s portfolio.Aperio Group reduced its stake in CMN by selling 306 shares or 3.01% in the most recent quarter. The Hedge Fund company now holds 9,861 shares of CMN which is valued at $707,625. Cantel Medical Corp. makes up approx 0.01% of Aperio Group’s portfolio.
Cantel Medical Corp. opened for trading at $75.81 and hit $76.09 on the upside on Thursday, eventually ending the session at $75.95, with a gain of 0.45% or 0.34 points. The heightened volatility saw the trading volume jump to 1,52,289 shares. Company has a market cap of $3,167 M.
On the company’s financial health, Cantel Medical Corp. reported $0.44 EPS for the quarter, beating the analyst consensus estimate by $ 0.08 according to the earnings call on Jun 8, 2016. Analyst had a consensus of $0.36. The company had revenue of $173.70 million for the quarter, compared to analysts expectations of $163.16 million. The company’s revenue was up 22.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.35 EPS.
Many Wall Street Analysts have commented on Cantel Medical Corp.. Cantel Medical Corp. was Initiated by Needham to “Hold” on Aug 24, 2016.
Cantel Medical Corp. is a provider of infection prevention and control products and services in the healthcare market. The Company’s segments include Endoscopy Water Purification and Filtration Healthcare Disposables Dialysis and Specialty Packaging. Its Endoscopy segment includes medical device reprocessing systems disinfectants detergents and other supplies. The Company’s Water Purification and Filtration segment includes water purification equipment and services filtration and separation products and disinfectants sterilization and decontamination products and services. Its Healthcare Disposables segment includes single-use infection prevention and control healthcare products. The Company’s Dialysis segment includes medical device reprocessing systems sterilants/disinfectants and dialysate concentrates. Its Specialty Packaging segment includes specialty packaging and thermal control products as well as related compliance training.